Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06451536
Status:
RECRUITING
Last Update Posted:
2024-06-11
First Post:
2024-05-17
Brief Title:
Ga-68 FAPI PET Before Immunotherapy
Sponsor:
Ankara University
Organization:
Ankara University
Study Overview
Official Title:
Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAPBI
Brief Summary:
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PETCT imaging which allows in vivo evaluation of FAP expression which is thought to be associated with immunosuppression and resistance to immunotherapy
Detailed Description:
Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study Patients will undergo Ga68 FAPI PETCT imaging within 10 days before the start of immunotherapy treatment and SUVmax SUVmean metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors Following this the routine treatment and follow-up of the patients will be carried out by their clinicians It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None